Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Novel glioblastoma therapeutics

Reference number
Coordinator Beactica AB
Funding from Vinnova SEK 2 000 000
Project duration December 2017 - December 2018
Status Completed
Venture Innovationsprojekt i företag 2017
Call innovationsprojekt i företag, Hösten 2017

Purpose and goal

The Beactica allosteric LSD1 modulator programme have advanced through lead generation to in vivo proof of principle in an advanced glioblastoma model, with an improved understanding of the mechanism of action.

Expected results and effects

The promising results from the advanced glioblastoma proof-of-principle model, and indication of efficacy in backup cancer indications, open the door for preclinical development and expansion into other indications.

Planned approach and implementation

Activities in the project have been distributed between chemistry and in vitro assays at Beactica, while key in vitro disease models have been performed as part of academic collaborations, and highly specialized contract research organizations have performed critical in vivo models. The semi-virtual organization proved to be highly flexible and able to handle complex studies with the required wide range of scientific and disciplines.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2017-04342

Page statistics